Urol. praxi. 2025;26(1):46-50 | DOI: 10.36290/uro.2025.024

Metabolic syndrome nad urinary track disorders

prof. MUDr. Miroslav Merta, CSc.
Ústav biologie a lékařské genetiky 1. LF UK a VFN, Praha

Metabolic syndrome (MetS) is a complex unit of various metabolic disorders, inclu­ding abdominal obesity, dyslipidemia, elevated blood pressure and increased fasting glycemia, which act in mutual interplay as important risk factors for multiple diseases, including disorders of urinary tract. Increasing body of evidence suggest that MetS and its individual components predispose not only to the development of malignant tumors notably carcinoma of kidney, prostate, ureter or urinary bladder but also to the development of other urological diseases, such as urolithiasis, benign prostate hypertrophy, male hypogonadism or erectile dysfunction. Some patophysiological mechanisms or paradoxal findings are not currently sufficiently understood and require further research. From a clinical point of view it is important to respect the fact, that for successfull prevention and management of multiple urological disorders an increased interdisciplinary cooperation aimed to treat and decrease predisposing risk metabolic factors is required.

Keywords: metabolic syndrome, diseases of urinary tract, urological diseases, diabetes mellitus, lipid disorder, arterial hypertension, insulin resistance.

Accepted: March 10, 2025; Published: March 24, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Merta M. Metabolic syndrome nad urinary track disorders. Urol. praxi. 2025;26(1):46-50. doi: 10.36290/uro.2025.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 24.3.2026

    References

    1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the Internatio­nal Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. Go to original source... Go to PubMed...
    2. Moore JX, Chaudhary N, Akinyemiju T, et al. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis. 2017;14:E24. Go to original source... Go to PubMed...
    3. Meigs JB, Rutter MK, Sullivan LM, et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30(5):1219-1225. Go to original source... Go to PubMed...
    4. Hamaguchi M, Kojima T, Takeda, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722-728. Go to original source... Go to PubMed...
    5. Mili N, Paschou SA, Goulis DG, et al. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74(3):478-497. Go to original source... Go to PubMed...
    6. Yarnoff BO, Hoerger TJ, Shrestha SS, et al. Modeling the impact of obesity on the lifetime risk of chronic kidney disease in the United States using updated estimates of GFR progression from the CRIC study. PLoS One. 2018;13(10):e0205530. Go to original source... Go to PubMed...
    7. Znaor A, Lortet-Tieulent J, Laversanne M. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-530. Go to original source... Go to PubMed...
    8. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245-257. Go to original source... Go to PubMed...
    9. Macleod LC, Hotaling JM, Wright JL, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol. 2013;190(5):1657-1661. Go to original source... Go to PubMed...
    10. Hendriks SH, Schrijnders D, van Hateren KJ, et al. Association between body mass index and obesity-related cancer risk in men and women with type 2 diabetes in primary care in the Netherlands: a cohort study (ZODIAC-56). BMJ Open. 2018;8(1):e018859. Go to original source... Go to PubMed...
    11. Suarez Arbelaez MC, Nackeeran S, Shah K, et al. Association between body mass index, metabolic syndrome and common urologic conditions: a cross-sectional study using a large multi-institutional database from the United States. Ann Med. 2023;55(1):2197293. Go to original source... Go to PubMed...
    12. Li X, Li N, Wen Y, et al. Metabolic syndrome components and renal cell cancer risk in Chinese males: a population-based prospective study. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54(6):638-643.
    13. Hidayat K, Du X, Zou SY, et al. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344. Go to original source... Go to PubMed...
    14. Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167(4):438-446. Go to original source... Go to PubMed...
    15. Graff RE, Sanchez A, Tobias DK, et al. Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies. Diabetes Care. 2018;41(7):1432-1437. Go to original source... Go to PubMed...
    16. Labadie BW, Liu P, Bao R, et al. BMI, irAE, and gene expression signatures associate with resistance to immune-check­point inhibition and outcomes in renal cell carcinoma. J Transl Med. 2019;17(1):386. Go to original source... Go to PubMed...
    17. Sanchez A, Furberg H, Kuo F, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol. 2020;21(2):283-293. Go to original source... Go to PubMed...
    18. Aune D, Mahamat-Saleh Y, Norat T, et al. Body fatness, diabetes, physical activity and risk of kidney stones: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2018;33(11):1033-1047. Go to original source... Go to PubMed...
    19. Vlachová K. Urolitiáza - metabolické poruchy a konzervativní léčba. Urol. praxi. 2023;24(1):37-41. Go to original source...
    20. Kim JH, Doo SW, Yang WJ, et al. The relationship between urinary stone components and visceral adipose tissue using computed tomography-based fat delineation. Urology. 2014;84(1):27-31. Go to original source... Go to PubMed...
    21. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293(4): 455-462. Go to original source... Go to PubMed...
    22. Noblett KL, Jensen JK, Ostergard DR. The relationship of body mass index to intra-abdominal pressure as measured by multichannel cystometry. Int Urogynecol J Pelvic Floor Dysfunct. 1997;8(6):323-326. Go to original source... Go to PubMed...
    23. Kristal AR, Arnold KB, Schenk JM, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol. 2007;177(4):1395-400. Go to original source... Go to PubMed...
    24. Ozden C, Ozdal OL, Urgancioglu G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51(1):199-203. Go to original source... Go to PubMed...
    25. Lv K, Yang G, Wu Y. The causal effect of metabolic syndrome and its components on benign prostatic hyperplasia: A univariable and multivariable Mendelian randomization study. Prostate. 2023;83(14):1358-1364. Go to original source... Go to PubMed...
    26. Ren J, Li Y, Zhang X. Correlation between metabolic syndrome and periurethral prostatic fibrosis: results of a prospective study. BMC Urol. 2024;24(1):38. Go to original source... Go to PubMed...
    27. Sousa AP, Costa R, Alves MG, et al. The Impact of Metabolic Syndrome and Type 2 Diabetes Mellitus on Prostate Cancer. Front Cell Dev Biol. 2022;10:843458. Go to original source... Go to PubMed...
    28. Troisi RJ, Weiss ST, Parker DR, et al. Relation of obesity and diet to sympathetic nervous system activity. Hypertension. 1991;17(5):669-677. Go to original source... Go to PubMed...
    29. Blanc-Lapierre A, Spence A, Karakiewicz PI, et al. Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada. BMC Public Health. 2015;15:913. Go to original source... Go to PubMed...
    30. Crawley D, Chamberlain F, Garmo H, et al. A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. Ecancermedicalscience. 2018;12:802. Go to original source... Go to PubMed...
    31. Carrageta DF, Oliveira PF, Alves MG, et al. Obesity and male hypogonadism: Tales of a vicious cycle. Obes Rev. 2019;20(8):1148-1158. Go to original source... Go to PubMed...
    32. Teplan V. Metabolický syndrom v nefrologii. Med. praxi. 2010;7(5):209-215.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.